2023-05-06 10:50:00
Orange with 6Medias, published on Saturday, May 06, 2023 at 12:50 p.m.
An American pharmaceutical group has announced encouraging results during the clinical trial of an experimental drug against Alzheimer’s disease, reports the Actu.fr site.
The American pharmaceutical group Eli Lilly welcomed, on Wednesday May 3, 2023, the results of the clinical trial of its new treatment developed against Alzheimer’s disease, donanemab. As a reminder, this neurodegenerative disease whose main symptom is memory loss, does not benefit, for the time being, from any treatment allowing a total cure, reports Actu.fr.
A medicine that is not a cure
The clinical trial of the American pharmaceutical group had approximately 1,700 participants, aged between 60 and 85, who had not yet reached an advanced stage of the disease.
According to the results put forward, this drug would have reduced by 36% the cognitive decline of the treated patients. Over the eighteen months of treatment, donanemab also reduced the loss of ability to perform daily tasks, such as driving, conversing or having hobbies, by 40%. However, the treatment can have serious side effects, such as edema or cerebral hemorrhage: three participants died.
If it can’t be considered a cure, the drug could open new doors in the quest to find a cure for Alzheimer’s disease, which has stalled for decades. Like other approved treatments, donanemab targets deposits of a protein called beta-amyloid, which appears to be responsible for destroying neurons in sufferers. “We are now entering the era of disease modification, where we could realistically hope to treat and maintain someone with Alzheimer’s disease, with long-term management of the disease rather than palliative care and support”, Dr Catherine Mummery, head of the cognitive disorders clinic at the National Hospital for Neurology and Neurosurgery in the United Kingdom, commented to the BBC.
The American laboratory announced that it would file an application for authorization with the American Medicines Agency (FDA), as well as in the world “as quickly as possible”.
1683380259
#promising #treatment